– USA, CA – Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel cancer immunotherapies based on tumor-infiltrating lymphocyte technology, today announced the appointment of Athena Countouriotis, M.D., to the company’s Board of Directors, effective June 10, 2019.
Dr. Countouriotis is the President and Chief Executive Officer of Turning Point Therapeutics and specialized in hematology and oncology in her professional career.
“Dr. Countouriotis has a long record of successful leadership in oncology drug development, and particular expertise in bringing novel therapies through clinical development,” commented Dr Maria Fardis, CEO of Iovance Biotherapeutics. “We are delighted to expand our Board with new members with deep drug development experience.”
About Dr Athena Countouriotis
Dr. Countouriotis previously served as Chief Medical Officer for multiple public biotechnology companies, including Adverum Biotechnologies, Halozyme Therapeutics, and Ambit Biosciences. Earlier in her career, Dr. Countouriotis led the development of products for Pfizer and Bristol-Myers Squibb, including Sutent, Mylotarg, Bosulif, and Sprycel. She currently serves on the board of directors at Turning Point Therapeutics and Trovagene.
“I am excited to join the board at such an important time for the company following the strong data shown at ASCO with LN-145 in cervical cancer and with lifileucel in advanced melanoma,” said Dr. Countouriotis. “Both therapies have such great potential to benefit patients and I look forward to working with the company and the board to make these therapies available to patients.”
Dr. Countouriotis holds an undergraduate degree from the University of California, Los Angeles and an M.D. from the Tufts University School of Medicine. She received training at the University of California, Los Angeles and at the Fred Hutchinson Cancer Research Center in the Pediatric Hematology-Oncology Program.
About Iovance Biotherapeutics, Inc.
Iovance Biotherapeutics intends to commercialize autologous cell therapy products that amplify the body’s own immune response to eradicate solid tumors or attack blood cancers. The company is currently conducting the pivotal study innovaTIL-01 in patients with metastatic melanoma. In addition, the company’s tumor infiltrating lymphocyte therapies are being investigated for the treatment of patients with locally advanced, recurrent or metastatic cancers including cervical, head and neck, and non-small cell lung cancer.
For more information: https://www.iovance.com
- Disclaimer - News, data and statement included in this release are intended exclusively for general information purposes. Talent4Boards accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the adequacy or accuracy of the information. No data or statement in this release should be considered for decisions about securities referred. Product and brand names used in this release maybe trademarks or registered trademarks of their respective owners.
Comments are closed.